PreveCeutical Medical Inc.
PREV
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 185.80% | 165.70% | 73.41% | -19.78% | 16.91% |
| Depreciation & Amortization | 28.38% | 20.55% | 5.48% | 2.78% | -27.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 175.28% | 148.50% | 62.11% | -18.79% | 13.83% |
| Operating Income | -175.28% | -148.50% | -62.11% | 18.79% | -13.83% |
| Income Before Tax | -124.30% | -100.03% | -45.40% | 9.03% | -158.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.30% | -100.03% | -45.40% | 9.03% | -158.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.30% | -100.03% | -45.40% | 9.03% | -158.04% |
| EBIT | -175.28% | -148.50% | -62.11% | 18.79% | -13.83% |
| EBITDA | -176.79% | -149.93% | -62.83% | 19.01% | -14.58% |
| EPS Basic | -110.53% | -100.00% | -53.33% | 5.88% | -216.67% |
| Normalized Basic EPS | -108.33% | -90.91% | -40.00% | 9.09% | -200.00% |
| EPS Diluted | -110.53% | -100.00% | -53.33% | 5.88% | -216.67% |
| Normalized Diluted EPS | -108.33% | -90.91% | -40.00% | 9.09% | -200.00% |
| Average Basic Shares Outstanding | 2.88% | 1.31% | 0.23% | 0.19% | 0.47% |
| Average Diluted Shares Outstanding | 2.88% | 1.31% | 0.23% | 0.19% | 0.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |